IQVIA Holdings Inc. (NYSE:IQV - Get Free Report) insider Eric Sherbet sold 4,446 shares of the stock in a transaction that occurred on Monday, November 9th. The shares were sold at an average price of $278.83, for a total transaction of $1,239,678.18. Following the transaction, the insider owned 24,989 shares in the company, valued at approximately $6,967,682.87. This represents a 15.10% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.
IQVIA Stock Performance
Shares of IQV stock opened at $271.11 on Friday. The firm has a market cap of $44.68 billion, a price-to-earnings ratio of 32.94, a PEG ratio of 2.44 and a beta of 1.16. IQVIA Holdings Inc. has a 52-week low of $154.50 and a 52-week high of $284.50. The company has a quick ratio of 0.83, a current ratio of 0.83 and a debt-to-equity ratio of 2.18. The company's 50 day moving average is $267.67 and its 200 day moving average is $211.75.
IQVIA (NYSE:IQV - Get Free Report) last posted its earnings results on Tuesday, October 27th. The medical research company reported $3.34 earnings per share for the quarter, topping analysts' consensus estimates of $3.26 by $0.08. The company had revenue of $4.43 billion during the quarter, compared to analyst estimates of $4.37 billion. IQVIA had a return on equity of 30.02% and a net margin of 8.05%. IQVIA's revenue was up 8.0% on a year-over-year basis. During the same quarter in the prior year, the business earned $3.00 earnings per share. On average, sell-side analysts anticipate that IQVIA Holdings Inc. will post 11.53 EPS for the current fiscal year.
Hedge Funds Weigh In On IQVIA
Several institutional investors and hedge funds have recently bought and sold shares of IQV. Pension & Wealth Management Advisors Inc. acquired a new position in shares of IQVIA during the third quarter worth $30,000. Compass Financial Management LLC acquired a new stake in shares of IQVIA in the 2nd quarter worth $27,000. Ascentis Independent Advisors acquired a new stake in shares of IQVIA in the 1st quarter worth $25,000. Elevation Wealth Partners LLC boosted its position in shares of IQVIA by 218.8% in the 2nd quarter. Elevation Wealth Partners LLC now owns 153 shares of the medical research company's stock worth $30,000 after purchasing an additional 105 shares in the last quarter. Finally, Balance Wealth Partners LLC purchased a new position in IQVIA during the 3rd quarter worth $43,000. 89.62% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
Several research analysts have recently commented on IQV shares. HSBC boosted their price target on IQVIA from $280.00 to $300.00 and gave the stock a "buy" rating in a research report on Tuesday, September 1st. JPMorgan Chase & Co. raised their price objective on IQVIA from $295.00 to $325.00 and gave the company an "overweight" rating in a research report on Wednesday, October 28th. Royal Bank Of Canada lifted their target price on IQVIA from $247.00 to $319.00 and gave the company an "outperform" rating in a research note on Tuesday, September 29th. Deutsche Bank reduced their target price on shares of IQVIA from $191.00 to $179.00 in a report on Thursday, October 15th. Finally, Stifel Nicolaus increased their price target on shares of IQVIA from $276.00 to $303.00 and gave the company a "buy" rating in a research report on Wednesday, October 14th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, IQVIA currently has a consensus rating of "Moderate Buy" and a consensus price target of $294.21.
Check Out Our Latest Report on IQVIA
IQVIA Company Profile
(
Get Free Report)
IQVIA Holdings Inc. provides clinical research services, healthcare data and analytics, and technology solutions to pharmaceutical, biotechnology, medical-device, and other healthcare organizations. Its services support the development and commercialization of medicines and other healthcare products. The company's offerings include clinical trial planning and management, real-world data and evidence, consulting, and software and technology platforms for life sciences research and commercial operations.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
